logo

For the Inventor, By the Inventor

Framingham, MA, United States of America

Timothy D Ocain

This inventor holds 17 USPTO granted patents, primarily in Monoclonal Antibodies. Top assignees: American Home Products Corporation, Wyeth, Millennium Pharmaceuticals Limited. Active years: 1991-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Timothy D Ocain. Retrieved from https://idiyas.com/inventor/timothy-d-ocain

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17

% Patents Active = 76.5

Average Co-Inventor Count = 3.0

ph-index = 10

Forward Citations = 573(Granted Patents)


Location History:

  • Princeton, NJ (US) (1991 - 1993)
  • Waltham, MA (US) (1996)
  • Framingham, MA (US) (1995 - 2011)

Company Filing History:

goldMedal8 out of 1,567 
 
American Home Products Corporation
 patents
silverMedal3 out of 1,309 
 
Wyeth
 patents
bronzeMedal2 out of 855 
 
Millennium Pharmaceuticals Limited
 patents
4. 2 out of 12 
 
Procept Corporation
 patents
5. 1 out of 1,268 
 
Dana-Farber-Cancer Institute Inc.
 patents
6. 1 out of 4,488 
 
Pfizer Corporation
 patents

Years Active: 1991-2011

Loading Chart...
Areas of Expertise:
Rapamycin Conjugates
Monoclonal Antibodies
ACE-2 Modulating Compounds
Caspase Activity
Immune Response Inhibition
Pyrimidocycloalkanes
Renin Inhibitors
Biotin Esters
Aromatic Compounds
Gem-Distributed Esters
Immunogen
Antibody Development
17 patents (USPTO):Explore Patents
1. 7897733 - Rapamycin conjugates and antibodies (2011-03-01),
2. 7279562 - Rapamycin conjugates (2007-10-09),
3. 7279561 - Anti-rapamycin monoclonal antibodies (2007-10-09),
4. 7247438 - Methods of identifying agents which enhance caspase activity (2007-07-24),
5. 7045532 - ACE-2 modulating compounds and methods of use thereof (2006-05-16),
6. 6632830 - ACE-2 inhibiting compounds and methods of use thereof (2003-10-14),
7. 6541612 - Monoclonal antibodies obtained using rapamycin position 27 conjugates as an immunogen (2003-04-01),
8. 6328970 - Rapamycin position 27 conjugates (2001-12-11),
9. 5739169 - Aromatic compounds for inhibiting immune response (1998-04-14),
10. 5708022 - Method for inhibiting immune response (1998-01-13),
11. 5504091 - Biotin esters of rapamycin (1996-04-02),
12. 5385910 - Gem-distributed esters of rapamycin (1995-01-31),
13. 5234936 - Pyrimidocycloalkanes as a II antagonists (1993-08-10),
14. 5095119 - Renin inhibitors (1992-03-10),
15. 5075451 - Pyrrolimidazolones useful as renin inhibitors (1991-12-24),

Title: The Innovative Journey of Timothy D Ocain

Introduction: Timothy D Ocain is a visionary inventor based in Framingham, Massachusetts. With a passion for creating groundbreaking solutions, Ocain has made significant contributions to the field of technology through his inventive spirit and dedication to innovation.

Latest Patents: Timothy D Ocain holds several patents in various technological domains, including advancements in artificial intelligence, renewable energy, and medical devices. His recent patents showcase his commitment to pushing the boundaries of what is possible in the world of innovation.

Career Highlights: Throughout his career, Timothy D Ocain has worked with leading tech companies to bring his inventions to life. His ability to blend creativity with technical expertise has led to the successful development of cutting-edge products that have made a positive impact on society.

Collaborations: Ocain has collaborated with top researchers, engineers, and scientists to further his innovative projects. By fostering partnerships with like-minded individuals, he has been able to leverage collective expertise and resources to drive his inventions forward.

Conclusion: Timothy D Ocain's relentless pursuit of innovation and his remarkable contributions to the tech industry have solidified his reputation as a pioneering inventor. His work continues to inspire future generations of inventors to think outside the box and create solutions that shape the world of tomorrow.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…